Clinical Trials Logo

Rhinitis, Allergic clinical trials

View clinical trials related to Rhinitis, Allergic.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT05129306 Withdrawn - Allergic Rhinitis Clinical Trials

Impact of RYALTRIS® Nasal Spray on Patients' Reported Outcomes

Start date: November 17, 2021
Phase:
Study type: Observational

A real world evidence study that aims to understand the impact of RYALTRIS® nasal spray in patients with Allergic Rhinitis over a 28-day period.

NCT ID: NCT04790487 Withdrawn - Allergic Rhinitis Clinical Trials

Chlorpheniramine Maleate Nasal Spray for Chronic Rhinitis

Start date: July 30, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

Allergic rhinitis is defined as the symptoms of sneezing, nasal itching, airflow obstruction, and, mostly, clear nasal discharge caused by IgE-mediated reactions against inhaled allergens and involving mucosal inflammation driven by T cells (Th2) auxiliary type 2. pollens and molds, as well as allergens from perennial interiors, such as dust mites, pets, pests, and some molds. The pattern of dominant allergens depends on the geographic region and degree of urbanization, but the general prevalence of sensitization to allergens does not vary among census districts in the United States. This research proposes to study a separate antihistamine in a nasal spray. It is important to note that this antihistamine is available without prescription (OTC) and has been studied intranasal since the 1950s1

NCT ID: NCT04670653 Withdrawn - Allergic Rhinitis Clinical Trials

Efficacy and Safety of Magnólia Nasal Gel in the Treatment of Allergic Rhinitis

Start date: August 1, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Magnólia nasal gel in the treatment of moderate-severe persistent or moderate-severe intermittent allergic rhinitis.

NCT ID: NCT04601324 Withdrawn - Allergic Rhinitis Clinical Trials

Allergic Rhinitis Combination Pharmacotherapy Efficacy Study

Start date: December 15, 2020
Phase: Phase 4
Study type: Interventional

Combination pharmacotherapy is often used in people who have failed mono-therapies in managing their bothersome allergic rhinitis symptoms . However, there is a paucity of research indicating the most effective combination therapies in managing allergic rhinitis. This study aims to evaluate the efficacy of oral antihistamine (rupatadine) combined with nasal steroid (fluticasone propionate) compared to a well-studied combination therapy of nasal steroid with nasal antihistamine spray (MP-AzeFlu).

NCT ID: NCT02988778 Withdrawn - Clinical trials for Rhinitis, Allergic, Perennial

Clinical Study, Non Inferiority Between Noex® 50µg Versus Busonid® 50µg in Treatment of Allergic Rhinitis

RINEX50
Start date: October 8, 2019
Phase: Phase 3
Study type: Interventional

This study is to evaluate non inferiority of Eurofarma budesonide nasal spray x referral Astrazeneca budesonide. Half patients will receive Eurofarma medication and half patients will receive Astrazeneca medication. There is no placebo group.

NCT ID: NCT02972866 Withdrawn - Clinical trials for Rhinitis, Allergic, Perennial

Clinical Study, Non Inferiority Between Noex® 32µg Versus Budecort Aqua® 32µg in Treatment of Alergic Rhinitis

RINEX32
Start date: June 2016
Phase: Phase 3
Study type: Interventional

This study is to evaluate non inferiority of Eurofarma budesonide nasal spary x referral Astrazeneca budesonide. Half patients will receive Eurofarma medication and half patients will receive Astrazeneca medication. There is no placebo group.

NCT ID: NCT02953379 Withdrawn - Allergic Rhinitis Clinical Trials

Efficacy and Safety of the Mometasone Nasal Gel in the Treatment of Persistent Allergic Rhinitis

Start date: May 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the non-inferiority of the clinical efficacy of the mometasone nasal gel in the treatment of allergic rhinitis.

NCT ID: NCT02953366 Withdrawn - Allergic Rhinitis Clinical Trials

Efficacy and Safety of the Mometasone Nasal Gel in the Treatment of Persistent Allergic Rhinitis

Start date: May 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the non-inferiority of the clinical efficacy of the mometasone nasal gel in the treatment of allergic rhinitis.

NCT ID: NCT01989897 Withdrawn - Allergic Rhinitis Clinical Trials

Effect of HSA or Saline Diluent on Immunotherapy Extract Stability as Determined by Graded ID Skin Tests

Start date: March 2013
Phase: Phase 1/Phase 2
Study type: Interventional

This is a double-blind study with respect to the diluents used, with patients known to be allergic to the specific allergen tested. Three study sites will be involved, each testing one allergen (Cat, Mite, Timothy grass pollen). Subjects who are known to be allergic to the allergen in question will be tested with serial three-fold dilutions to determine the ID 50 and relative extract potency using the method described by Turkeltaub.

NCT ID: NCT01055756 Withdrawn - Allergic Rhinitis Clinical Trials

Clinical Trial Of The Effectiveness Of The Product Cloratadd D (Loratadine + Pseudoephedrine Sulfate) Produced By The Laboratory EMS S/A, Compared To The Drug Claritin D Produced By Schering-Plough S/A, In Patients With Allergic Rhinitis

Start date: January 2010
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the clinical efficacy of the drug Cloratadd D ® (loratadine + pseudoephedrine sulfate - EMS S/A) compared to the drug Claritin D ® (loratadine + pseudoephedrine sulfate - Schering Plough) in patients with allergic rhinitis by quantification of the scores of clinical parameters (signs and symptoms) and laboratory (nasal flow) down through time.